The Relationship of Negative Schizophrenia to Parkinsonism

References

• Abramsky O., Litvin O. Autoimmune response to dopamine as a possible mechanism in the pathogenesis of Parkinson's disease and schizophrenia. Perspectives in Biology and Medicine 1978; 24: 104–114
   Google Scholar
• Agid Y., Javoy-Agid F., Ruberg M., Pillon B., Dubois B., Duyckaerts C., Hauw J. J., Baron J. C., Scatton B. Progressive supranuclear palsy; Anatomoclinical and biochemical considerations. Advances in Neurology, M. D. Vahr, K. J. Bergmann, 1986; vol. 45: 191–206
   Google Scholar
• Albrech P., Torrey E. F., Boone E. Raised cytomegalovirus antibody level in cerebrospinal fluid of schizophrenic patients. Lancet 1980; 2: 769–772
   PubMed Web of Science ®Google Scholar
• Alexopolous G. S. Complaints in schizophrenics with tardive dyskinesia. Journal of Nervous and Mental Disorders 1979; 167: 125–127
   PubMed Web of Science ®Google Scholar
• Alizan T. S., Terasaki P. I., Yahr M. D. HLA-B14 antigen and postencephalitic Parkinson's disease: their association in an American Jewish ethnic group. Archives of Neurology 1980; 37: 542–544
   PubMedGoogle Scholar
• Alpert M., Diamond F., Weisenfreund J., Taleporos E., Friedhoff A. J. The neuroleptic hypothesis: Study of the covariation of the extrapyramidal and therapeutic drug effect. British Journal of Psychiatry 1978; 133: 169–175
   PubMed Web of Science ®Google Scholar
• Alpert M., Rush M. Comparison of affects in Parkinson's disease and schizophrenia. Psychopharmacology Bulletin 1983; 196: 118–120
   Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd edition. APA, Washington, DC 1980
   Google Scholar
• Andreasen N. C. Thought, language, and communication disorders: I. Clinical assessment, definition of terms, and evaluation of their reliability. Archives of General Psychiatry 1979; 36: 1315–1321
   PubMed Web of Science ®Google Scholar
• Andreasen N. C. Scale for the Assessment of Negative Symptoms (SANS). University of Iowa., Iowa City 1981
   Google Scholar
• Andreasen N. C. Negative symptoms in schizophrenia: Definition and reliability. Archives of General Psychiatry 1982; 39: 784–788
   PubMed Web of Science ®Google Scholar
• Andreasen N. C., Olsen S. A., Dennert J. W., Smith M. R. Ventricular enlargement in schizophrenia: Definition and prevalence. American Journal of Psychiatry 1982; 139: 292–296
   PubMed Web of Science ®Google Scholar
• Andreasen N. C. Positive vs. negative schizophrenia: A critical evaluation. Schizophrenia Bulletin 1985; 11: 380–389
   PubMed Web of Science ®Google Scholar
• Angrist B., Rotrosen J., Gershon S. Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. Psychopharmacology 1980; 72: 17–19
   PubMed Web of Science ®Google Scholar
• Angrist B., Peselow E., Rubinstein M. Partial improvement in negative schizophrenic symptoms after amphetamine. Psychopharmacology 1982; 78: 128–130
   PubMed Web of Science ®Google Scholar
• Angst J., Stassen H. H., Woggon B. Effect of neuroleptics on positive and negative symptoms and the deficit state. Psychopharmacology 1989; 99: S41–S46
   Web of Science ®Google Scholar
• Appenzeller O., Goss J. E. Autonomic deficits in Parkinson's syndrome. Archives of Neurology 1971; 24: 50–57
   PubMedGoogle Scholar
• Arregui A., MacKay A. V. P., Iversen L. L., Spokes E. G. S. Reduction of angiotensin-converting enzyme in substantia nigra in early-onset schizophrenia. New England Journal of Medicine 1979; 300: 502–503
   PubMed Web of Science ®Google Scholar
• Ashcroft G. W., Crawford T. B. B., Eccelson D., Sharman D. F., Macdougall E. G., Stanton J. B., Binnis J. K. 5-hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatric or neurologic diseases. Lancet 1966; 2: 1049–1052
   PubMed Web of Science ®Google Scholar
• Asso D. WAIS scores in a group of Parkinson patients. British Journal of Psychiatry 1969; 115: 555–556
   PubMed Web of Science ®Google Scholar
• Ayd F. J. A survey of drug-induced extrapyramidal reactions. Journal of the American Medical Association 1961; 175: 1054–1060
   PubMed Web of Science ®Google Scholar
• Baldessarini R. J., Tarsy D. Relationship of the action of neuroleptic drugs to the pathophysiology of tardive dyskinesia. International Review of Neurobiology, J. R. Smythes, R. J. Bradley. Academic Press, New York 1979
   Google Scholar
• Barbeau A., Porcher E. New data on the genetics of Parkinson's disease. Canadian Journal of Neurological Sciences 1982; 9: 53–66
   PubMed Web of Science ®Google Scholar
• Baron J. A. Cigarette smoking and Parkinson's disease. Neurology 1986; 36: 1490–1496
   PubMed Web of Science ®Google Scholar
• Barr M. L. The Human Nervous System, 3rd ed. Harper & Row, Hagerstown, MD 1979
   Google Scholar
• Becker H., Grau H., Schneider E. CT examination series of Parkinson patients. Cranial Computerized Tomography, W. Lauksch, E. Kazner. Springer Verlag, New York 1976; 249–251
   Google Scholar
• Benedek L. Zwangmassiges Schreien in Anfallen als postencephalitische Hyperkinesie. Zeitschrift fur die Gesamte Neurologie und Psychiatrie 1925; 98: 17–26
   Google Scholar
• Bentin S., Silverberg R., Gordon H. W. Asymmetrical cognitive deterioration in demented and Parkinson patients. Cortex 1981; 17: 533–544
   PubMed Web of Science ®Google Scholar
• Berger L., Gauthier S., Leblanc R. Akinetic mutism and Parkinsonism associated with obstructive hydrocephalus. Canadian Journal of Neurological Sciences 1985; 12: 255–258
   PubMed Web of Science ®Google Scholar
• Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. Jorunal of Neurological Sciences 1973; 20: 415–455
   PubMed Web of Science ®Google Scholar
• Bes A., Guell A., Fabre N. Cerebral blood flow studied by Xenon-133 inhalation technique in Parkinsonism: Loss of hyperfrontal pattern. Journal of Cerebral Blood Flow and Metabolism, 3: 33–37
   PubMed Web of Science ®Google Scholar
• Birkmayer W., Dannielzyk W., Neumacher E., Riedere P. Nucleus ruber and L-DOPA psychosis: biochemical postmortem findings. Journal of Neural Transmission 1974; 35: 93–116
   PubMed Web of Science ®Google Scholar
• Birkmayer W., Knoll J., Riederer P., Youdim M. G. H., Hars V., Marton J. Increased life expectancy resulting from addition of L-deprenyl to madopar treatment in Parkinson's disease: A longterm study. Journal of Neural Transmission 1985; 64: 113–127
   PubMed Web of Science ®Google Scholar
• Bitton V., Melamed E. Coexistence of severe Parkinsonism and tardive dyskinesia as side-effects of neuroleptic therapy. Journal of Clinical Psychiatry 1984; 45: 28–30
   PubMed Web of Science ®Google Scholar
• Bjorklund A., Lindvall O. Regeneration of normal terminal innervation patterns by central noradrenergic neurons after 5,7-dihydroxytryptoamine-induced axotomy in the adult rat. Brain Research 1979; 171: 271–294
   PubMed Web of Science ®Google Scholar
• Bleuler E. Dementia Praecox or The Group of Schizophrenias, J. Zinkin. International Universities Press, New York 1950, Translated by
   Google Scholar
• Blumer D., Benson D. F. Personality changes with frontal and temporal lobe lesions. Psychiatric Aspects of Neurologic Disease, D. F. Benson, D. Blumer. Grune & Stratton, New York 1975; 151–170
   Google Scholar
• Bogerts B., Meertz E., Schonfeldt-Bausch R. Basal ganglia and limbic system pathology in schizophrenia. A morphometric study of brain volume and shrinkage. Archives of General Psychiatry 1985; 42: 784–791
   PubMed Web of Science ®Google Scholar
• Boller F., Passafiume D., Keefe N. C., Rogers K., Morrow L., Kim Y. Visuospatial impairment in Parkinson's disease. Role of perceptual and motor factors. Archives of Neurology 1984; 41: 485–490
   PubMed Web of Science ®Google Scholar
• Borison R. The recognition and management of drug-induced movement disorders (reversible type). Presented at the 137th Annual Meeting of the American Psychiatric Association, Los Angeles, CA, 1984
   Google Scholar
• Bowen F. P., Hoehn M. M., Yahr M. D. Parkinsonism: Alterations in spatial orientation as determined by a route-walking test. Neuropsychologia 1972; 10: 355–361
   PubMed Web of Science ®Google Scholar
• Bowers M. B., Goodman E., Sim V. M. Some behavior changes in man following anticholines-terase administration. Journal of Nervous and Mental Disease 1964; 138: 383–389
   PubMed Web of Science ®Google Scholar
• Bowers M. B. Central dopamine turnover in schizophrenic syndromes. Archives of General Psychiatry 1974; 31: 50–54
   PubMed Web of Science ®Google Scholar
• Bowman M., Lewis M. S. Sites of subcortical damage in diseases which resemble schizophrenia. Neuropsychologia 1980; 18: 597–601
   PubMed Web of Science ®Google Scholar
• Boyd A. E., Lebovitz H. E., Feldman J. M. Endocrine function and glucose metabolism in patients with Parkinson's disease and their alteration by L-dopa. Journal of Clinical Endocrinology and Metabolism 1971; 33: 829–837
   PubMed Web of Science ®Google Scholar
• Brambilla F., Guastalla A., Guerrini A. Glucose-insulin metabolism in chronic schizophrenia. Diseases of the Nervous System 1976; 37: 98–103
   PubMedGoogle Scholar
• Breier A., Wolkowitz O. M., Doran A. R., Roy A., Hommer D. W., Pickar D. Neuroleptic responsivity of negative and positive symptoms in schizophrenia. American Journal of Psychiatry 1987; 144: 1549–1555
   PubMed Web of Science ®Google Scholar
• Burton J. L., Cartlidge M., Cartlidge N. E. F., Shuster F. Sebum secretion in Parkinsonism. British Journal of Dermatology 1973; 88: 263–266
   PubMed Web of Science ®Google Scholar
• Buscaino V. M. Le cause anatoma-pathologiche della manifetatione schizophrenica della demenza precoce. Ric Pathologia Nervus Mental 1920; 25: 193–226
   Google Scholar
• Butterworth R. F., Belanger F., Barveau A. Hypokinesia produced by anterolateral hypothalamic 6-hydroxydopamine lesions and its reversal by some antiparkinson drugs. Pharmacology, Biochemistry & Behavior 1977; 8: 41–45
   Web of Science ®Google Scholar
• Calne D. B. Pharmacology of Parkinsonism. Parkinsonism: Physiology, pharmacology and treatment, D. B. Calne. Edward Arnold Publishers, London 1970; 49–67
   Google Scholar
• Cannon T. D., Fuhrmann M., Mednick S. A., Machon R. A., Parnas J., Schulsinger F. Third ventricular enlargement and reduced electrodermal responsivenss. Psychophysiology 1988; 25: 153–156
   PubMed Web of Science ®Google Scholar
• Carpenter W. T., Heinrichs D. W., Alphs L. D. Treatment of negative schizophrenia. Schizophrenia Bulletin 1985; 11: 440–452, 1985
   PubMed Web of Science ®Google Scholar
• Cash R., Dennis T., L'Heureux R., Raisman R., Javoy-Agid F., Scatton B. Parkinson's disease and dementia: Norepinephrine and dopamine in locus coeruleus. Neurology 1987; 37: 42–46
   PubMed Web of Science ®Google Scholar
• Chase T. N. Catecholamine metabolism and neurologic disease. Biochemical Pharmacology 1974; 23(suppl)941–946
   Google Scholar
• Chien C., DiMascio A., Cole J. O. Antiparkinson agents and depot phenothiazines. American Journal of Psychiatry 1974; 131: 86–90
   PubMed Web of Science ®Google Scholar
• Chouinard G., Jones B. D. Schizophrenia as a dopamine deficiency disease. Lancet 1978; 1: 99–100
   Google Scholar
• Cornblatt B. A., Lenzenweger M. F., Dworkin R. H., Erlenmeyer-Kimling L. Positive and negative schizophrenic symptoms, attention, and information processing. Schizophrenia Bulletin 1985; 11: 397–408
   PubMed Web of Science ®Google Scholar
• Costall B., Naylor R. J. The role of telencephalic dopaminergic systems in the mediation of apomorphine-stereotypes behavior. European Journal of Pharmacology 1973; 24: 8–24
   PubMed Web of Science ®Google Scholar
• Costall B., Naylor R. J. The hypothesis of different dopamine receptor mechanisms. Life Sciences 1981; 28: 215–229
   PubMed Web of Science ®Google Scholar
• Cox S. M., Ludwig A. M. Neurological soft signs and psychopathology: Findings in schizophrenia. Journal of Nervous and Mental Disease 1979; 167: 161–165
   PubMed Web of Science ®Google Scholar
• Crane G. E. Pseudoparkinsonism and tardive dyskinesia. Archives of Neurology 1972; 27: 426–430
   PubMedGoogle Scholar
• Crow T. J. Molecular pathology of schizophrenia: More than one disease process?. British Medical Journal 1980; 280: 66–68
   PubMed Web of Science ®Google Scholar
• Crow T. J. Positive and negative schizophrenic symptoms and the role of dopamine. British Journal of Psychiatry 1980a; 137: 383–386
   PubMed Web of Science ®Google Scholar
• Crow T. J. Is schizophrenia an infectious disease?. Lancet 1983; 1: 173–175
   PubMed Web of Science ®Google Scholar
• Crow T. J. The two-syndrome concept: Origins and current status. Schizophrenia Bulletin 1985; 11: 471–486
   PubMed Web of Science ®Google Scholar
• Crow T. J., Johnstone E. C., McClelland H. A. The coincidence of schizophrenia and Parkinsonism: some neurochemical implications. Psychological Medicine 1976; 6: 227–233
   PubMed Web of Science ®Google Scholar
• Cummings J. L., Frankel M. Gilles de la Tourette's syndrome and the neurological basis for obsessions and compulsions. Biological Psychiatry 1985; 20: 1117–1126
   Web of Science ®Google Scholar
• D'Antona R., Baron J. C., Samson Y., Serdaru M., Viader F., Agid Y., Cambier J. Subcortical dementia: Frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy. Brain 1985; 108: 785–799
   PubMed Web of Science ®Google Scholar
• Davis J. M. Comparative doses and costs of antipsychotic medication. Archives of General Psychiatry 1976; 33: 858–861
   PubMed Web of Science ®Google Scholar
• Davis K. L., Hollister L. E., Overall J., Johnson A., Train K. Physostigmine: effects on cognition and affect in normal subjects. Psychopharmacology 1976; 51: 23–27
   PubMed Web of Science ®Google Scholar
• DeFraites E. G., Davis K. L., Berger P. A. Coexisting tardive dyskinesia and Parkinsonism. Biological Psychiatry 1977; 12: 267–272
   PubMed Web of Science ®Google Scholar
• Den Hartog Jager W. A., Bethlem J. The distribution of Lewy bodies in the central and autonomic nervous system in idiopathic paralysis agitans. Journal of Neurology, Neurosurgery and Psychiatry 1960; 23: 283–290
   PubMed Web of Science ®Google Scholar
• De Jong D. Parkinson's disease: statistics. Journal of Neurosurgery 1966; 24(suppl)149–155
   Google Scholar
• De Lancy-Horne D. J. Performance on delayed response task by patients with Parkinsonism. Journal of Neurology, Neurosurgery and Psychiatry 1971; 34: 192–194
   PubMed Web of Science ®Google Scholar
• Dening T. R. Blinking and essential blepharospasm. Comprehensive Psychiatry 1987; 28: 83–92
   PubMed Web of Science ®Google Scholar
• Desai N. G., Ganghadar B. N., Pradhan N., Chanabasavanna S. M. Treatment of negative schizophrenia with d-amphetamine. American Journal of Psychiatry 1984; 141: 723–724
   PubMed Web of Science ®Google Scholar
• Dewan M. J., Pandurangi A. K., Lee S. H., Ramachandran T., Levy B., Boucher M., Voza witz A., Major L. F. Central brain morphology in chronic schizophrenic patients: A controlled CT study. Biological Psychiatry 1983; 18: 1133–1140
   PubMed Web of Science ®Google Scholar
• Dide M. M. Les syndromes hypothalamiques et al dyspsychogenese. Review Neurologique 1934; 6: 941–943
   Google Scholar
• Domino E. F., Olds M. E. Cholinergic inhibition of self-stimulation behavior. Journal of Pharmacology 1968; 164: 202–211
   Google Scholar
• Donlong P. T., Stenson R. L. Neuroleptic-induced extrapyramidal symptoms. Diseases of the Nervous System 1976; 37: 629–635
   PubMedGoogle Scholar
• Eaton W. E. Epidemiology of schizophrenia. Epidemiology Reviews 1985; 7: 105–126
   PubMed Web of Science ®Google Scholar
• Economo C. Encephalitis Lethargica–Its sequelae and Treatment, K. O. Newman. University Press, Oxford 1931, Translated by
   Google Scholar
• Ehringer H., Hornykiewicz O. Verteilung von noradrenalin und dopamin im Gehirn des Menschen und ihre Verhalten beim Erkrankungen des Extrapyramidaler Systems. Wiener Klinische Wochenschrift 1960; 38: 1236–1239
   Web of Science ®Google Scholar
• Elner A. M., Kandel E. I. Study of the carbohydrate metabolism in Parkinsonism. ZH Nerypathology Psikhiatry IM SS Korsakova 1965; 65: 46–50
   PubMedGoogle Scholar
• Endicott J. E., Spitzer R. L. Diagnostic interview: The schedule for affective disorders and schizophrenia. Archives of General Psychiatry 1978; 35: 837–844
   PubMed Web of Science ®Google Scholar
• Fahn S., Mayeux R. Unilateral Parkinson's disease and contralateral tardive dyskinesia: A unique case with successful therapy that may explain the pathophysiology of these two disorders. Journal of Neural Transmission 1980; 16(suppl)179–185
   Google Scholar
• Fairweather D. S. Psychiatric aspects of the postencephalitic syndrome. Journal of Mental Science 1974; 93: 201–254
   Google Scholar
• Fanget F., Claustrat B., Dalery J., Brun J., Terra J. L., Marie-Cardine M., Guyotat J. Nocturnal plasma melatonin levels in schizophrenic patients. Biological Psychiatry 1989; 25: 499–501
   PubMed Web of Science ®Google Scholar
• Fann W. E., Lake C. R. On the coexistence of Parkinsonism and tardive dyskinesia. Diseases of the Nervous System 1974; 35: 324–326
   PubMedGoogle Scholar
• Fayen M., Goldman M. G., Moulthrop M. A., Luchins D. J. Differential memory function with dopaminergic versus anticholinergic treatment of drug-induced extrapyramidal symptoms. American Journal of Psychiatry 1988; 145: 483–496
   PubMed Web of Science ®Google Scholar
• Ferrier I. N., Arendt J., Johnstone E. C., Crow T. J. Reduced nocturnal melatonin secretion in chronic schizophrenia: Relationship to body weight. Clinical Endocrinology 1982; 17: 181–187
   PubMed Web of Science ®Google Scholar
• Ferrier I. N., Roberts G. W., Crow T. J., Johnstone E. C., Owens D. G. C., Lee V. C., O'Shaughnessy D., Adrian T. E., Polak J. M., Bloom S. R. Reduced cholecytokinin-like and somatostatin-like immureactivity is associated with negative symptoms in schizophrenia. Life Sciences 1983; 33: 475–492
   PubMed Web of Science ®Google Scholar
• Fishman M. The brain stem in psychosis. British Journal of Psychiatry 1975; 126: 414–422
   PubMed Web of Science ®Google Scholar
• Fleischhaker W. W., Barnas C., Stuppack C., Unterweger B., Hinterhuber H. Zotepine in the treatment of negative symptoms in chronic schizophrenia. Pharmacopsychiatry 1987; 20: 58–60
   PubMed Web of Science ®Google Scholar
• Flint A. The skin in Parkinson's disease. Primary Care 1977; 4: 475–480
   PubMedGoogle Scholar
• Flint A. J., Wastwood R. Frontal lobe syndrome and depression in old age. Journal of Geriatric Psychiatry and Neurology 1988; 1: 53–55
   PubMedGoogle Scholar
• Forno L. S. Pathology of Parkinsonism: A preliminary report of 24 cases. Journal of Neurosurgery 1966; 24(Suppl)266–271
   Google Scholar
• Forno L. S. The Lewy body in Parkinson's disease. Advances in Neurology, M. D. Vahy, K. J. Bergmann, 1986; vol. 45: 35–43
   Google Scholar
• Friedhoff A. J. A strategy for developing novel drugs for the treatment of schizophrenia. Schizophrenia Bulletin 1983; 9: 555–562
   PubMed Web of Science ®Google Scholar
• Friedman J. H., Max J., Swift R. Idiopathic Parkinson's disease in a chronic schizophrenic patient: Long term treatment with clozapine and L-dopa. Clinical Neuropharmacology 1987; 10: 470–475
   PubMed Web of Science ®Google Scholar
• Friedman J. H., Lannon M. C. Clozapine in the treatment of psychosis in Parkinson's disease. Neurology 1989; 39: 1219–1221
   PubMed Web of Science ®Google Scholar
• Fuxe K., Goldstein M., Hokfelt T., Johnson T., Lidbrik P. Dopaminergic involvement in hypothalamic function: Extrahypothalamic and hypothalamic control. A neuroanatomical analysis. Advances in Neurology 1974; 5: 405–419
   PubMedGoogle Scholar
• Gath J., Jorgensen A., Sjaastad O. Pneumencephalographic findings in Parkinsonism. Archives of Neurology 1975; 32: 769–773
   PubMedGoogle Scholar
• George L., Neufeld R. W. J. Cognition and symptomatology in schizophrenia. Schizophrenia Bulletin 1985; 11: 264–285
   Google Scholar
• Gerlach J., Luhdorf K. The effect of L-dopa on young patients with simple schizophrenia treated with neuroleptic drugs: A double-blind cross-over trial, with madopar and placebo. Psychopharmacologia 1975; 44: 105–110
   PubMed Web of Science ®Google Scholar
• Gerlach J. Pathophysiological mechanisms underlying tardive dyskinesia. Dyskinesia: Research and Treatment, D. E. Casey, T. N. Chase, A. V. Christensen, J. Gerlach. Springer-Verlag, Berlin 1985; 98–103
   Google Scholar
• Gibb W. R. G., Lees A. J. Prevalence of Lewy body in Alzheimer's disease. Annals of Neurology 1989; 26: 691–692
   PubMed Web of Science ®Google Scholar
• Goetz C. G. Drug-induced Parkinsonism and idiopathic Parkinson's disease. Archives of Neurology 1983; 40: 325–326
   PubMedGoogle Scholar
• Goldberg E. Akinesia, tardive dysmentia, and frontal lobe disorder in schizophrenia. Schizophrenia Bulletin 1985; 11: 255–263
   PubMed Web of Science ®Google Scholar
• Goldberg T. E., Weinberger D. R., Berman K. F., Pliskin N. H., Podd M. H. Further evidence for dementia of the prefrontal type in schizophrenia? A controlled study of teaching the Wisconsin Card Sorting Test. Archives of General Psychiatry 1987; 44: 1008–1014
   PubMed Web of Science ®Google Scholar
• Grasset N., Brun R. Etude du film sebace de sujets sains et de patients atteints d'epilepsie ou de maladie de Parkinson. Dermatologica 1959; 119: 232–237
   PubMedGoogle Scholar
• Green M., Walker E. Neuropsychological performance and positive and negative symptoms in schizophrenia. Journal of Abnormal Psychology 1985; 94: 460–469
   PubMed Web of Science ®Google Scholar
• Greenfield J. G., Bosanquet F. D. The brainstem in Parkinsonism. Journal of Neurology, Neurosurgery and Psychiatry 1953; 16: 213–226
   PubMed Web of Science ®Google Scholar
• Gross M., Bannister R., Godwin-Austen R. Orthostatic hypotension in Parkinson's disease. Lancet 1972; 1: 174–176
   PubMed Web of Science ®Google Scholar
• Growdon J. H., Corkin S. Cognitive impairments in Parkinson's disease. Advances in Neurology, M. D. Yahr, K. J. Bergmann, 1986; vol. 45: 383–392
   Google Scholar
• Gruzelier J. H., Hammond M. V. The effect of chlorpromazine upon psychophysiological, endocrine, and information processing measures in schizophrenia. Journal of Psychiatric Research 1978; 14: 167–182
   PubMed Web of Science ®Google Scholar
• Gubbay S. S., Barwick D. D. Two cases of accidental hypothermia in Parkinson's disease with unusual EEG findings. Journal of Neurology, Neurosurgery and Psychiatry 1966; 29: 459–466
   PubMed Web of Science ®Google Scholar
• Gureje O. Topographic subtypes of tardive dyskinesia in schizophrenic patients aged less than 60 years: Relationship to demographic, clinical, treatment, and neuropsychological variables. Journal of Neurology, Neurosurgery and Psychiatry 1988; 51: 1525–1530
   PubMed Web of Science ®Google Scholar
• Hall A. The origin and purpose of blinking. British Journal of Ophpthalmology 1945; 29: 445–467
   PubMed Web of Science ®Google Scholar
• Hoehn M. M., Crowley T. J., Rutledge C. O. Dopamine correlates of neurological and psychological status in untreated Parkinsonism. Journal of Neurology, Neurosurgery, and Psychiatry 1976; 39: 941–951
   PubMed Web of Science ®Google Scholar
• Hoffman W. F., Labs S. M., Casey D. E. Neuroleptic-induced Parkinsonism in older schizophrenics. Biological Psychiatry 1987; 22: 427–439
   PubMed Web of Science ®Google Scholar
• Holden J. M. C., Itil T. M., Keskiner A. The treatment of lobotomized schizophrenic patients with butaperazine. Current Therapeutic Research 1969; 11: 418–428
   PubMed Web of Science ®Google Scholar
• Hollister L. E., Glazener F. S. Concurrent paralysis agitans and schizophrenia. Diseases of the Nervous System 1961; 22: 187–189
   PubMedGoogle Scholar
• Honigfeld G., Patin J., Singer J. Clozapine: antipsychotic activity in treatment-resistant schizophrenics. Advances in Therapy 1984; 1: 77–97
   Google Scholar
• Hopf A. Uber histopathologische veranderungen im Pallidum und Striatum bei Schizophrenie. Proceedings of the International Congress of Neuropathology. Rosenberg & Sellinger, TurinItaly 1952; vol. 3: 629–635
   Google Scholar
• Horn S. Some psychological factors in Parkinsonism. Journal of Neurology, Neurosurgery and Psychatry 1974; 37: 27–31
   PubMed Web of Science ®Google Scholar
• Hornykiewicz O. Brain neurotransmitter changes in Parkinson's disease. Movement Disorders, C. D. Marsden, S. Fahn. Butterworths Publishers, Boston 1982; 41–58
   Google Scholar
• Hornykiewicz O., Kish S. J. Biochemical pathophysiology of Parkinson's disease. Advances in Neurology, M. D. Yahr, K. J. Bergmann, 1986; vol. 45: 19–34
   Google Scholar
• Houston J. P., Maas J. W., Bowden C. L., Contreras S. A., McIntyre K. L., Javors M. A. Cerebrospinal fluid HVA, central brain atrophy, and clinical state in schizophrenia. Psychiatry Research 1986; 19: 207–214
   PubMed Web of Science ®Google Scholar
• Howard R. S., Lees A. J. Encephalitis lethargica. A report of four recent cases. Brain 1987; 110: 19–33
   PubMed Web of Science ®Google Scholar
• Huber S. J., Paulson G. W. Relationship between primitive reflexes and severity in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 1986; 49: 1298–1300
   PubMed Web of Science ®Google Scholar
• Hurst J. H., LeWitt P. A., Burns R. S., Foster N. L., Lovenberg W. CSF dopamine-beta-hydroxylase activity in Parkinson's disease. Neurology 1985; 35: 565–568
   PubMed Web of Science ®Google Scholar
• Jackson J. H. Remarks on evolution and dissolution of the nervous system. Journal of Mental Sciences 1887; 33: 25–48
   Google Scholar
• Jackson J. A., Free G. B. M., Pike H. V. The psychic manifestations in paralysis agitans. Archives of Neurology and Psychiatry 1923; 10: 680–684
   Google Scholar
• Jankovic J. Pathophysiology and clinical assessment of motor symptoms in Parkinson's disease. Handbook of Parkinson's disease, W. C. Killer. Marcel Dekker, New York 1987; 99–126
   Google Scholar
• Javoy-Agid F., Agid F. Is the mesocortical dopaminergic system involved in Parkinson's disease?. Neurology 1980; 30: 1326–1330
   PubMed Web of Science ®Google Scholar
• Javoy-Agid F., Pique L., Bertagna X., Taquet H., Studler J. M., Cesselin F., Epelbaum J., Agid Y. Biochemistry of the Hypothalamus in Parkinson disease. Neurology 1984; 34: 672–675
   PubMed Web of Science ®Google Scholar
• Javoy-Agid F., Ruberg M., Hirsch E., Cash R., Raisman R., Taquet H., epelbaum J., Scatton B., Duyckaerts C., Agid Y. Recent progress in the neurochemistry of Parkinson's disease. Recent Developments in Parkinson's Disease, S. Fahn, C. D. Marsden, P. Jenner, P. Teychenne. Raven Press, New York 1986; 67–83
   Google Scholar
• Jellife S. E. The mental pictures in schizophrenia and in epidemic encephalitis. American Journal of Psychiatry 1927; 6: 413–465
   Google Scholar
• Jellinger K. Overview of morphological changes in Parkinson's disease. Advances in Neurology, M. D. Yahr, K. J. Bergmann, 1986; vol. 45: 1–18
   Google Scholar
• Jellinger K. Pathology of Parkinsonism. Recent development in Parkinson's disease, S. Fahn, C. D. Marsden, P. Jenner, P. Teychenne. Raven Press, New York 1986; 33–66
   Google Scholar
• Jenkyn L. R., Walsh D. B., Culver C. M., Reeves A. G. Clinical signs in diffuse cerebral dysfunction. Journal of Neurology, Neurosurgery and Psychiatry 1977; 40: 956–966
   PubMed Web of Science ®Google Scholar
• Jernigan T. Anatomic and CT studies of psychiatric disorders. American Handbook of Psychiatry, P. Berger, H. K. H. Brodie. Basic Books Inc Publishers, New York 1986; vol. 8: 213–235
   Google Scholar
• Johnstone E. C., Crow T. J., Frith C. D., Stevens M., Kreel I., Husband J. The dementia of dementia praecox. Acta Psychiatrica Scandinavica 1976; 57: 305–324
   Web of Science ®Google Scholar
• Johnstone E. C., Crow T. J., Frith C. D., Husband J., Kreel I. Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet 1976a; 2: 924–926
   PubMed Web of Science ®Google Scholar
• Johnstone E. C., Crow T. J., Ferrier I. N., Frith C. D., Owens D. G. C., Bourne R. C., Gamble S. J. Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychological Medicine 1983; 13: 513–527
   PubMed Web of Science ®Google Scholar
• Johnstone E. C., Owens D. G. C., Frith C. D., Crow T. J. The relative stability of positive and negative features in chronic schizophrenia. British Journal of Psychiatry 1987; 150: 60–64
   PubMed Web of Science ®Google Scholar
• Kaminsky R., Moriarty T. M., Bodine J., Wolf D. E., Davidson M. Effect of famotidine on deficit symptoms of schizophrenia. Lancet 1990; 335: 1351–1352
   PubMed Web of Science ®Google Scholar
• Kanazawa I. Clinical pathophysiology of basal ganglia disease. Handbook of Clinical Neurology, P. J. Vinken, G. W. Bruyn, H. L. Klawans. Elsevier Science Publishers, Amsterdam 1986; vol. 5: 65–85
   Google Scholar
• Kane J., Honigfeld G., Singer J., Meltzer H. Y. Clozapine in treatment resistant schizophrenia. Archives of General Psychiatry 1988; 45: 789–796
   PubMed Web of Science ®Google Scholar
• Karson C. N., Stabu R., Kleinman J. E. Drug effect on blink rates in rhesus monkey. Biological Psychiatry 1981; 16: 249–254
   PubMed Web of Science ®Google Scholar
• Karson C. N. Spontaneous eye blink rates and dopaminergic systems. Brain 1983; 106: 643–653
   PubMed Web of Science ®Google Scholar
• Kastin A. J., Redding T. W., Schally A. V. MSH activity in rat pituitaries after pinealectomy. Proceedings of the Society of Experimental Biology and Medicine 1967; 124: 1275–1277
   PubMed Web of Science ®Google Scholar
• Kastin A. J., Viosca S., Nair R. M. G., Schally A. V., Miller M. C. Interactions between pineal, hypothalamus and pituitary involving melatonin, MSH release inhibiting factor and MSH. Endocrinology 1972; 91: 1323–1328
   PubMed Web of Science ®Google Scholar
• Kaufman C. A., Jeste D. V., Shelton R. C., Linnoila M., Kafka M. S., Wyatt R. J. Noradrenergic and neuroradiological abnormalities in tardive dyskinase. Biological Psychiatry 1986; 21: 799–812
   PubMed Web of Science ®Google Scholar
• Kawamura T., Kinoshita M., Iwasaki Y., Nemoto H. Low-dose dexamethasone suppression test in Japanese patients with Parkinson's disease. Journal of Neurology 1987; 234: 264–265
   PubMed Web of Science ®Google Scholar
• Kay S. R. Positive and Negative Syndromes in Schizophrenia: Assessment and Research. Brunner/Mazel, New York, (in press).
   Google Scholar
• Kay S. R., Sandyk R. Interpretation of the positive-negative distinction. Positive and Negative Syndromes in Schizophrenia: Assessment and Research, S. R. Kay. Brunner/Mazel., New York, (in press)
   Google Scholar
• Kay S. R., Sevy S. Pyramidal model of schizophrenia. Schizophrenia Bulletin, (in press)
   Google Scholar
• Kay S. R., Singh M. M. The positive-negative distinction in drug-free schizophrenic patients: Stability, response to neuroleptics, and prognostic significance. Archives of General Psychiatry, (in press)
   Web of Science ®Google Scholar
• Kay S. R., Singh M. M. Cognitive abnormality in schizophrenia: A dual process model. Biological Psychiatry 1979; 14: 155–176
   PubMed Web of Science ®Google Scholar
• Kay S. R. Arousal and schizophrenia: Toward a dual-process model and framework for research. JSAS Catalog of Selected Documents in Psychology 1981; 11: 35–36, (Whole No. 2256)
   Google Scholar
• Kay S. R., Opler L. A. L-dopa in the treatment of negative schizophrenic symptoms. International Journal of Psychiatry in Medicine 1985; 15: 293–298
   PubMed Web of Science ®Google Scholar
• Kay S. R., Opler L. A., Fiszbein A. Significance of positive and negative syndromes in chronic schizophrenia. British Journal of Psychiatry 1986; 149: 439–448
   PubMed Web of Science ®Google Scholar
• Kay S. R., Fiszbein A., Opler L. A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987; 13: 261–275
   PubMed Web of Science ®Google Scholar
• Kay S. R., Sandyk R. Negative symptoms in schizophrenia: Clinical relevance and biological significance. Presented at the Collegium International Neuropsychopharmacologicum, KyotoJapan, 1990
   Google Scholar
• Keshavan M. S., Yeragani V. K. Primitive reflexes in psychiatry. Lancet 1987; 1: 1264
   PubMed Web of Science ®Google Scholar
• Kizer J. S., Palkovits M., Brownstein M. J. The projections of the A8, A9 and A10 dopaminergic cell bodies: evidence for anigral-hypothalamic-median eminence dopaminergic pathway. Brain Research 1976; 108: 363–370
   PubMed Web of Science ®Google Scholar
• Klawans H. L. The pharmacology of tardive dyskinesia. American Journal of Psychiatry 1973; 130: 82–86
   PubMed Web of Science ®Google Scholar
• Klawans H. L. Psychiatric side effects during the treatment of Parkinson's disease. Journal of Neural Transmission 1988; 27(suppl)117–122
   Google Scholar
• Knoll J., Dallo J., Yen T. T. Striatal dopamine, sexual activity and lifespan. Longevity of rats treated with (–) deprenyl. Life Sciences 1989; 45: 525–531
   PubMed Web of Science ®Google Scholar
• Kolb B., Whishaw I. Performance of schizophrenic patients on tests sensitive to left or right frontal, temporal or parietal function in neurological patients. Journal of Nervous and Mental Disease 1983; 171: 435–443
   PubMed Web of Science ®Google Scholar
• Krawiecka M., Goldberg D., Vaughan M. A. Standardized psychiatric assessment for rating chronic patients. Acta Psychiatrica Scandinavica 1977; 55: 299–308
   PubMed Web of Science ®Google Scholar
• Kvorning S. A. Excretion of skin lipids in patients with Parkinson's syndrome. Acta Dermatologica Venerica 1952; 32(supp, 28–29)201–203
   Google Scholar
• Langston J. W., Forno L. S. The hypothalamus in Parkinson disease. Annals of Neurology 1978; 3: 129–133
   PubMed Web of Science ®Google Scholar
• Lesch A., Bogerts B. The diencephalon in schizophrenia: Evidence for reduced thickness of the periventricular grey matter. European Archives of Psychiatry and Neurological Sciences 1984; 234: 212–219
   PubMedGoogle Scholar
• Lewy F. H. Die Lehre vom Tonus und der Bewegung. Springer., Berlin 1923
   Google Scholar
• Lidsky T. I., Weinhold P. M., Levine F. M. Implications of basal ganglionic dysfunction for schizophrenia. Biological Psychiatry 1979; 14: 3–12
   PubMed Web of Science ®Google Scholar
• Lindstrom L. H. Low HVA and normal 5-HIAA CSF level in drug free schizophrenic patients compared to healthy volunteers: Correlations to symptomatology and family history. Psychiatry Research 1985; 14: 265–273
   PubMed Web of Science ®Google Scholar
• Lindvall O., Bjorklund A., Moore R. Y., Stevevi U. Mesencephalic dopamine neurons projecting to neocortex. Brain Research 1974; 81: 325–331
   PubMed Web of Science ®Google Scholar
• Lipman I. J., Boykin M. E., Flora R. E. Glucose intolerance in Parkinson's disease. Journal of Chronic Diseases 1974; 27: 573–579
   PubMedGoogle Scholar
• Luchins D. J., Jackman H., Meltzer H. Y. Lateral ventricular size and drug-induced Parkinsonism. Psychiatry Research 1983; 9: 9–16
   PubMed Web of Science ®Google Scholar
• Luria A. R. Higher Cortical Functions in Man. Basic Books., New York 1966
   Google Scholar
• MacKay A. V. P. Positive and negative schizophrenic symptoms and the role of dopamine. Discussion, 1. British Journal of Psychiatry 1980; 137: 379–383
   PubMed Web of Science ®Google Scholar
• MacKay A. V. P., Iversen L. L., Rossor M., Spokes E., Bird E., Arregui A., Creese I., Synder S. H. Increased brain dopamine and dopamine receptors in schizophrenia. Archives of General Psychiatry 1982; 39: 991–997
   PubMed Web of Science ®Google Scholar
• Malarkey W. B., Cyrus J., Paulson G. W. Dissociation of growth hormone and prolactin secretion in Parkinson's disease following L-dopa therapy. Journal of Clinical Endocrinology and Metabolism 1974; 34: 229–235
   Google Scholar
• Markianos M., Tripodianakis J. Low plasma dopamine beta-hydroxylase in demented schizophrenics. Biological Psychiatry 1985; 20: 94–119
   PubMed Web of Science ®Google Scholar
• Marsden C. D., Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychological Medicine 1980; 10: 55–72
   PubMed Web of Science ®Google Scholar
• Marshall J. F., Richardson J. S., Teitelbaum P. Nigrostriatal bundle damage and the lateral hypothalamic syndrome. Journal of Comparative Psychology 1974; 87: 808–830
   Web of Science ®Google Scholar
• Marttila R. J., Eskola J., Paivarina M., Rinne U. K. Immune functions in Parkinson's disease. Advances in Neurology, R. G. Hassler, J. F. Christ. Raven Press, New York 1984; vol. 40: 315–323
   Google Scholar
• Maser J. D., Keith S. J. CT scan and schizophrenia–report on a workshop. Schizophrenia Bulletin 1983; 9: 265–273
   PubMed Web of Science ®Google Scholar
• Mason S. T. Noradrenaline and behavior. Trends in Neuroscience 1979; 2: 82–84
   Web of Science ®Google Scholar
• Maudsley H. The Pathology of the Mind, 3rd ed. Appleton, New York 1899; 113
   Google Scholar
• Mayeux R. Depression and dementia in Parkinson's disease. Movement Disorders, C. D. Marsden, S. Fahn. Butterworths International Medical Reviews, London 1982; 75–95
   Google Scholar
• McCowan P. K., Cook L. C. The mental aspect of chronic epidemic encephalitis. Lancet 1928; I: 1316–1320
   Google Scholar
• Meltzer H. Y., Busch D., Fang V. S. Hormones, dopamine receptors and schizophrenia. Psychoneuroendocrinology 1981; 6: 17–36
   PubMed Web of Science ®Google Scholar
• Meltzer H. Y., Sommers A. A., Luchins D. J. The effect of neuroleptics and other psychotrophic drugs on negative symptoms in schizophrenia. Journal of Clinical Psychopharmacology 1986; 6: 329–338
   PubMed Web of Science ®Google Scholar
• Meltzer H. Y. Biological studies in schizophrenia. Schizophrenia Bulletin 1987; 13: 77–111
   PubMed Web of Science ®Google Scholar
• Merriam A. E., Kay S. R., Opler L. A., Kushner S., van Praag H. M. Neurological signs and the positive-negative distinction in schizophrenia. Biological Psychiatry, (in press)
   Google Scholar
• Mettler F. A. Perceptual capacity, functions of the corpus striatum and schizophrenia. Psychiatric Quarterly 1955; 29: 89–97
   PubMed Web of Science ®Google Scholar
• Mettler F. A., Crandell A. Relation between Parkinsonism and psychiatric disorder. Journal of Nervous and Mental Disease 1959; 129: 551–557
   Web of Science ®Google Scholar
• Mindham R. H. S. Psychiatric symptoms in Parkinsonism. Journal of Neurology, Neurosurgery and Psychiatry 1970; 32: 188–191
   Google Scholar
• Miwa S., Inagaki C., Fujewara M., Takaori S. The activities of noradenergic and dopaminergic neurons systems in experimental hydrocephalus. Journal of Neurosurgery 1982; 57: 67–73
   PubMed Web of Science ®Google Scholar
• Morel-Maroger A. Effects of levodopa on frontal signs in Parkinsonism. British Medical Journal 1977; 2: 1543
   PubMed Web of Science ®Google Scholar
• Morgan L. O., Gregory H. S. Pathological changes in the tuber cinerum in a group of psychoses. Journal of Nervous and Mental Disease 1935; 82: 286–298
   Google Scholar
• Morris J. C., Drazer M., Fulling K., Grant E. A., Goldring J. Clinical and pathological aspects of Parkinsonism in Alzheimer's disease. A role for extranigral factors?. Archives of Neurology 1989; 46: 651–657
   PubMedGoogle Scholar
• Mortimer J. A., Pirozzolo F. J., Hansch E. C., Webster D. D. Relationship of motor symptoms to intellectual deficits in Parkinson's disease. Neurology 1982; 32: 133–137
   PubMed Web of Science ®Google Scholar
• Moylan J. J., Saldias C. A. Developmental reflexes and cortical atrophy. Annals of Neurology 1979; 5: 499–500
   PubMed Web of Science ®Google Scholar
• Mukherjee S., Rosen A. M., Cardenas C., Varia V., Olarte S. Tardive dyskinesia in psychiatric outpatients. Archives of General Psychiatry 1982; 39: 466–469
   PubMed Web of Science ®Google Scholar
• Myers R. D. Temperature regulation: neurochemical systems in the hypothalamus. The Hypothalamus, W. Haymaker, E. Andersen, W. J. H. Nauta. Charles C. Thomas., Springfield, Illinois 1969
   Google Scholar
• Narabayashi H., Kondo T., Nagatsu T., Hayashi A., Suzuki T. DL-thereo-3,4-dihydroxyph-enylserine for freezing symptom in Parkinsonism. Advances in Neurology, R. G. Hassler, J. F. Christ. Raven Press, New York 1984; vol. 40: 497–502
   Google Scholar
• Nasrallah H. A., Jacoby C. G., McCalley-Whitters M., Kuperman S. Cerebral ventricular enlargement in subtypes of chronic schizophrenia. Archives of General Psychiatry 1982; 39: 774–777
   PubMed Web of Science ®Google Scholar
• Nasrallah H. A., Kuperman S., Jacoby C. G., McCalley-Whitters M., Hamra B. Clinical correlates of sulcal widening in chronic schizophrenia. Psychiatry Research 1983; 10: 237–242
   PubMed Web of Science ®Google Scholar
• National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). Department of Health, Education, and Welfare, Washington, DC 1974
   Google Scholar
• Nieto D., Escobar A. Major Psychoses. Pathology of the Nervous System, J. Minckler. McGraw-Hill Book Co., New York 1972; vol. 3: 2654–2665
   Google Scholar
• Nieto A., Nieto D. The red nucleus, the substantia nigra and the pineal gland responsible for mental illness. International Journal of Neuroscience 1988; 32: 277–278
   Web of Science ®Google Scholar
• Nyback H., Berggren B. M., Nyman H., Sedvall G., Wiesel F. A. Cerebroventricular volume, cerebrospinal fluid monoamine metabolites, and intellectual performance in schizophrenic patients. Neurology and Neurobilogy–Catecholamine. Part C: Neuropharmacology and Central Nervous System–Therapeutic Aspects, E. Usdin, A. Carlson, A. Dahlstrom, J. Engel. Alan R Liss Inc., New York 1984; 161–165
   Google Scholar
• Ohama E., Ikuta F. Parkinson's disease: Distribution of Lewy bodies and monoamine neuron system. Acta Neuropathologica 1976; 34: 311–319
   PubMed Web of Science ®Google Scholar
• Opler L. A., Kay S. R., Rosado V., Lindemayer J. P. Positive and negative syndromes in chronic schizophrenic inpatients. Journal of Nervous and Mental Disease 1984; 172: 317–325
   PubMed Web of Science ®Google Scholar
• Overall J. E., Gorham D. R. Brief Psychiatric Rating Scale. Psychological Reports 1962; 10: 799–812
   Web of Science ®Google Scholar
• Owens D. G. C., Johnstone E. C., Crow T. J., Frith C. D., Jagoe J. R., Kreel L. Lateral ventricular size in schizophrenia: relationship to the disease process and its clinical manifestations. Psychological Medicine 1985; 15: 27–41
   PubMed Web of Science ®Google Scholar
• Pandurangi A. K., Dewan M. J., Lee S. H., Ramachandran T., Levy B. F., boucher M., Yoz awitz A., Major L. The ventricular system in chronic schizophrenic patients. A controlled computed tomography study. British Journal of Psychiatry 1984; 144: 172–176
   PubMed Web of Science ®Google Scholar
• Paulson G., Gottleib G. Developmental reflexes: The reappearance of fetal and neonatal reflexes in aged patients. Brain 1968; 91: 37–52
   PubMed Web of Science ®Google Scholar
• Payne R. W. Cognitive abnormalities. Handbook of Abnormal Psychology, H. J. Eysenck. Pitman Medical Press, London 1973; 420–483
   Google Scholar
• Pearce J., Hassan A., Gallagher H. Primitive reflex activity in primary and symptomatic Parkinsonism. Journal of Neurology, Neurosurgery and Psychiatry 1968; 31: 501–504
   PubMed Web of Science ®Google Scholar
• Pearce J. M. S., Flowers K., Pearce I., Pratt A. E. Clinical, psychometric and CAT scan correlations in Parkinson's disease. Research Progress in Parkinson's disease, F. Cliford Rose, R. Capildeo. Pitman Medical, Kent 1981; 43–52
   Google Scholar
• Perutz A., Lustig B. Zur physiologie der Fettausscheidung und der Hautoberflache. Biochemische Zentraschrift 1933; 261: 128–131
   Google Scholar
• Peuskins J., De Cuyper H. J. A., Bollen J., Eneman M., Wilms G. Risperidone: A new approach in the treatment of schizophrenia. Treatment of Negative Symptoms in Schizophrenia. Oxford Clinical Communications, Oxford 1989
   Google Scholar
• Pfeiffer R. F., Hsieh H. H., Diercks M. J., Glaeske C., Jefferson A., Cheng S. C. Examethasone suppression test in Parkinson's disease. Advances in Neurology, M. D. Yahr, K. J. Bergmann. Raven Press, New York 1986; vol. 45: 439–442
   Google Scholar
• Pique L., Jegou S., Bertagna X., Javoy-Agid F., Seurin D., Proeschel M. F., Girard F., Agid Y., Vaudry H., Luton J. P. Pro-opiomelanocortin peptides in the human hypothalamus: Comparative studies between normal subjects and Parkinson patients. Neuroscience Letters 1985; 54: 141–146
   PubMed Web of Science ®Google Scholar
• Pirozzolo F. J., Hansch E. C., Mortimer J. A. Dementia in Parkinson disease: A neuropsychological analysis. Brain and Cognition 1982; 1: 71–83
   PubMedGoogle Scholar
• Pochi P. E., Strauss J. S., Mescon H. Sebum production and fractional 17 ketosteroid excretion in parkinsonism. Journal of Investigative Dermatology 1962; 38: 45–51
   PubMed Web of Science ®Google Scholar
• Pogue-Geile M. F., Harrow M. Negative and positive symptoms in schizophrenia and depression: A Followup. Schizophrenia Bulletin 1984; 10: 371–387
   PubMed Web of Science ®Google Scholar
• Pogue-Geile M. F., Harrow M. Negative symptoms in schizophrenia: Their longitudinal course and prognostic significance. Schizophrenia Bulletin 1985; 11: 427–439
   PubMed Web of Science ®Google Scholar
• Pogue-Geile M. F., Zubin J. Negative symptoms in schizophrenia: A conceptual and empirical review. International Journal of Mental Health 1988; 16: 3–45
   Web of Science ®Google Scholar
• Poirier L. J. The development of animal models for studies in Parkinson's disease. Recent Advances in Parkinson's Disease, F. H. McDowell, C. H. Markham. FA Davis, Philadelphia 1971; 83–117
   Google Scholar
• Portin R., Raininko R., Rinne U. K. Neuropsychological disturbances and cerebral atrophy determined by computerized tomography in parkinsonian patients with long-term levodopa treatment. Advances in Neurology, R. G. Hassler, J. F. Christ. Raven Press, New York 1984; vol. 40: 219–227
   Google Scholar
• Post F. Persistent Persecutory States of the Elderly. Pergamon Press, London 1966
   Google Scholar
• Potkin S. G., Weinberger D. R., Linnoila M., Wyatt R. J. Low CSF 5-hydroxyindioleacetic acid in schizophrenic patients with enlarged cerebral ventricles. American Journal of Psychiatry 1983; 140: 21–25
   PubMed Web of Science ®Google Scholar
• Pouplard A., Emile J. Autoimmunity in Parkinson's disease. Advances in Neurology, R. G. Hassler, J. F. Christ. Raven Press, New York 1984; vol. 40: 307–313
   Google Scholar
• Proctor F., Riklan M., Cooper S. T., Teuber H. L. Judgement of visual and postural vertical by parkinsonism patients. Neurology 1964; 14: 287–293
   PubMed Web of Science ®Google Scholar
• Rabins P. V., Pauker S., Thomas J. Can schizophrenia begin after age 44?. Comprehensive Psychiatry 1984; 25: 290–294
   PubMed Web of Science ®Google Scholar
• Rabins P., Pearlson G., Jayaram G., Steele C., Tune L. Increased ventricle-to-brain ratio in late-onset schizophrenia. American Journal of Psychiatry 1987; 144: 1216–1218
   PubMed Web of Science ®Google Scholar
• Rafal R. D., Posner M. I., Walker J. A., Friedrich F. J. Cognition and the basal ganglia. Separating mental and motor components of performance in Parkinson's disease. Brain 1984; 107: 1083–1094
   PubMed Web of Science ®Google Scholar
• Rainero I., Kaye A., May C., Durso R., Katz D. I., Albert M. L., Wolfe N., Pinessi L., Friedland R. P., Rapoport S. I. Alpha-melanocyte stimulating hormonelike immunoreactivity is increased in cerebrospinal fluid of patients with Parkinson's disease. Archives of Neurology 1988; 45: 1224–1227
   PubMedGoogle Scholar
• Rajput A. H., Rozdilsky B., Hornykiewicz O., Shannak K., Lee T., Seeman P. Reversible drug-induced parkinsonism. Clinicopathologic study of two cases. Archives of Neurology 1982; 39: 644–646
   PubMedGoogle Scholar
• Redmond D. E., Maas J. W., Kling A., Dekirmenjian H. Changes in primate social behavior after treatment with alpha-methyl-para-tyrosine. Psychosomatic Medicine 1971; 33: 97–113
   PubMed Web of Science ®Google Scholar
• Richardson M. A., Craig T. J. The coexistence of Parkinsonism-like symptoms and tardive dyskinesia. American Journal of Psychiatry 1982; 139: 341–343
   PubMed Web of Science ®Google Scholar
• Rieder R. O., Donnely E. F., Herdt J. R., Waldman I. N. Sulcal prominence in young chronic schizophrenic patients: CT scan findings associated with impairment on neuropsychological tests. Psychiatry Research 1979; 1: 1–8
   PubMed Web of Science ®Google Scholar
• Rifkin A., Quitkin F., Klein D. F. Akinesia: A poorly recognized drug-induced extrapyramidal behavioral disorder. Archives of General Psychiatry 1975; 32: 672–674
   Web of Science ®Google Scholar
• Rifkin A. The risks of longterm neuroleptic treatment of schizophrenia: Especially depressive and akinesia. Acta Psychiatrica Scandinavica 1981; 63(supp)129–134
   PubMed Web of Science ®Google Scholar
• Rogers D., Lees A. J., Trimble M., Stern G. M. Concept of bradyphernia: A neuropsychiatric approach. Advances in Neurology, M. D. Yahr, K. J. Bergmann, 1986; vol. 45: 447–455
   Google Scholar
• Rose R. M., Sachar E. Endocrine disturbances in psychiatric disorders. Textbook of Endocrinology, R. H. Williams. Saunders, Philadelphia 1981
   Google Scholar
• Rosen A. M., Mukherjee S., Olarte S., Varia V., Cardenas C. C. Perception of tardive dyskinesia in outpatients receiving maintenance neuroleptics. American Journal of Psychiatry 1982; 139: 372–373
   PubMed Web of Science ®Google Scholar
• Rosen J., Silk K. R., Rice H. E., Smith C. B. Platelet alpha-2 adrenergic dysfunction in negative symptom schizophrenia: A preliminary study. Biological Psychiatry 1985; 20: 539–545
   PubMed Web of Science ®Google Scholar
• Ross E. D., Stewart R. M. Akinetic mutism from hypothalamic damage: successful treatment with dopamine agonists. Neurology 1981; 31: 1435–1439
   PubMed Web of Science ®Google Scholar
• Roth M. The natural history of mental disorder in old age. Journal of Mental Science 1955; 101: 281–301
   PubMed Web of Science ®Google Scholar
• Roy M., Boyer L., Barbeau A. A prospective study of 50 cases of familial Parkinson's disease. Canadian Journal of Neurological Sciences 1983; 10: 37–42
   PubMed Web of Science ®Google Scholar
• Saffer D., Metcalfe M., Coopen A. Abnormal dexamethasone suppression test in Type II schizophrenia?. British Journal of Psychiatry 1985; 147: 721–723
   PubMed Web of Science ®Google Scholar
• Sandyk R., Decina P., Caracci G., Scapicchio P. Seborrhea and melanocyte stimulating hormone in drug-induced parkinsonism. International Journal of Neuroscience, (in press).
   Google Scholar
• Sandyk R., Iacono R. P. Early vs. late onset Parkinson's disease: The role of the locus coeruleus. International Journal of Neuroscience, (in press)
   Google Scholar
• Sandyk R., Kay S. R., Iacono R. P. Diabetes mellitus as a risk factor for drug-induced Parkinsonism in schizophrenia. International Journal of Neuroscience, (in press)
   Google Scholar
• Sandyk R., Kay S. R. Interpretation of the positive-negative distinction. Positive and Negative Syndromes in Schizophrenia: Assessment and Research, S. R. Kay. Brunner/Mazel, New York, (in press a).
   Google Scholar
• Sandyk R., Kay S. R. Sulcal prominence and neuroleptic-induced akathisia. Biological Psychiatry, (in press b)
   Google Scholar
• Sandyk R., Kay S. R. Pineal calcification: Relationship to age of onset of schizophrenia. International Journal of Neuroscience, (in press c)
   Google Scholar
• Sandyk R., Kay S. R. Parkinsonian tremor in schizophrenia is associated with cortical atrophy. International Journal of Neuroscience, (in press d)
   Google Scholar
• Sandyk R., Kay S. R. Tardive dyskinesia is not associated with features of negative schizophrenia. International Journal of Neuroscience, (in press e)
   Google Scholar
• Sandyk R., Kay S. R. Subjective awareness of abnormal involuntary movements in schizophrenic patients with tardive dyskinesia. International Journal of Neuroscience, (in press f)
   Google Scholar
• Sandyk R., Kay S. R. Tardive dyskinesia is associated with positive schizophrenia. International Journal of Neuroscience, (in press g)
   Google Scholar
• Sandyk R., Kay S. R. Diabetes mellitus as a clinical marker of idiopathic Parkinson's disease in schizophrenic patients with neuroleptic-induced parkinsonism. International Journal of Neuroscience, (in press h).
   Google Scholar
• Sandyk R., Kay S. R. The role of pineal melatonin functions in the pathophysiology of schizophrenia: A review and hypothesis. Schizophrenia Bulletin, (in press i)
   Google Scholar
• Sandyk R., Kay S. R. Pineal calcification is related to drug-induced parkinsonism. International Journal of Neuroscience, (in press j)
   Google Scholar
• Sandyk R. Mechanisms of recovery in MPTP-induced parkinsonism. Neuroscience 1988; 27: 727–729
   PubMed Web of Science ®Google Scholar
• Sandyk R. Pro-opiomelanocortin (POMC) processing in Parkinson's disease. International Journal of Neuroscience 1989; 46: 201–204
   PubMed Web of Science ®Google Scholar
• Sandyk R. Autoimmune mechanisms in Parkinson's disease. International Journal of Neuroscience 1989; 48: 369–372
   PubMed Web of Science ®Google Scholar
• Sandyk R. Melanocyte stimulating hormone and tardive dyskinesia. Biological Psychiatry 1990; 27: 677–678
   Web of Science ®Google Scholar
• Sandyk R. Pineal melatonin functions: Possible relevance to Parkinson's disease. International Journal of Neuroscience 1990; 50: 37–53
   PubMed Web of Science ®Google Scholar
• Sandyk R., Fleming J., Brennan M. J. W. The head retraction reflex–its specificity in Parkinson's disease. Clinical Neurology and Neurosurgery 1982; 84: 159–162
   PubMed Web of Science ®Google Scholar
• Sandyk R., Fisher H. Serotonin in involuntary movement disorders. International Journal of Neuroscience 1988; 42: 185–205
   PubMed Web of Science ®Google Scholar
• Sandyk R., Iacono R. P. Hypothalamic-mediated immune mechanisms and their relevance to the pathoetiology of Parkinson's disease. International Journal of Neuroscience 1986; 32: 979–981
   Web of Science ®Google Scholar
• Sandyk R., Iacono R. P., Bamford C. R. The hypothalamus in Parkinson's disease. Italian Journal of Neurological Sciences 1987; 8: 227–234
   PubMedGoogle Scholar
• Schooler N. R., Kane J. M. Research diagnoses of tardive dyskinesia. Archives of General Psychiatry 1982; 39: 486–487
   PubMed Web of Science ®Google Scholar
• Schwartz L., Munoz R. Blood sugar levels in patients treated with chlorpromazine. American Journal of Psychiatry 1968; 125: 253–255
   PubMed Web of Science ®Google Scholar
• Seidman L. J. Schizophrenia and brain dysfunction: An integration of recent neurodiagnostic findings. Psychological Bulletin 1983; 94: 195–238
   PubMed Web of Science ®Google Scholar
• Selby G. Cerebral atrophy and parkinsonism. Journal of the Neurological Sciences 1968; 6: 517–559
   PubMed Web of Science ®Google Scholar
• Serrati B. Influenza del sistema nervoso sull secrezione sebacea; osservazioni e ricerche cliniche. Rivera di Patholgia Nervosa 1938; 52: 377–423
   Google Scholar
• Shelton R. C., Karson K. N., Doran A. R., Pickar D., Bigelow L. B., Weinberger D. R. Cerebral structural pathology in schizophrenia: evidence for a selective prefrontal cortical defect. American Journal of Psychiatry 1988; 145: 154–163
   PubMed Web of Science ®Google Scholar
• Sheppard M. A., Merlis S. Drug-induced extrapyramidal symptoms: Their incidence and treatment. American Journal of Psychiatry 1967; 123: 886–889
   PubMed Web of Science ®Google Scholar
• Shuster S., Thody A. J., Plummer N., Goolamali S. K., Bates D. Melanocyte stimulating hormone and parkinsonism. Lancet 1973; 1: 463–465
   PubMed Web of Science ®Google Scholar
• Silman R. E., Leone R. M., Hooper R. J. L., Preece M. A. Melatonin, and pineal gland and human puberty. Nature 1979; 282: 301–303
   PubMed Web of Science ®Google Scholar
• Simpson G. M., Angus J. W. S. Drug-induced extrapyramidal disorders. Acta Psychiatrica Scandinavica 1970; 212(suppl)1–58
   Google Scholar
• Simpson G. M., Lee J. H., Zoubok B., Gardos G. A rating scale for tardive dyskinesia. Psychopharmacology 1979; 64: 171–179
   PubMed Web of Science ®Google Scholar
• Singh M. M., Kay S. R., Opler L. A. Anticholinergic-neuroleptic antagonism in terms of positive and negative symptoms of schizophrenia: implications for psychobiological subtyping. Psychological Medicine 1987; 17: 39–48
   PubMed Web of Science ®Google Scholar
• Sommers A. A. “Negative symptoms”: conceptual and methodological problems. Schizophrenia Bulletin 1985; 11: 364–379
   PubMed Web of Science ®Google Scholar
• Spiegel E. A., Wycis H. T., Schor H., Schwartz H., Fabiani F. R. (1968) The incidence of vegetative symptoms in Parkinson patients with and without bradykinesia. 3rd Parkinson Symposium, Edinburgh, May, 1968
   Google Scholar
• Spitzer R. L., Endicott J. E., Robins E. Research Diagnostic Criteria (RDC) for a Select Group of Functional Disorders (3rd ed.). New York State Psychiatric Institute, Biometrics Research, New York 1978
   Google Scholar
• Spokes E. G. S., Garrett N. J., Rosser M. N., Iversen L. L. Distribution of GABA in post-mortem brain tissue from control, psychotic and Huntington's chorea subjects. Journal of Neurological Sciences 1980; 48: 303–313
   PubMed Web of Science ®Google Scholar
• Sroka H., Elizan T. S., Yahr M. D., Burger A., Mendoza M. R. Organic mental syndrome and confusional states in Parkinson's disease. Relationship to computerized tomographic signs of cerebral atrophy. Archives of Neurology 1981; 38: 339–342
   PubMedGoogle Scholar
• Stein L., Wise C. D. Possible etiology of schizophrenia: Progressive damage to the noradrenergic reward system by 6-hydroxydopamine. Science 1971; 171: 1032–1036
   PubMed Web of Science ®Google Scholar
• Steiner I., Gomori G. M., Melamed E. Features of brain atrophy in parkinson's disease. A CT scan study. Neuradiology 1985; 27: 158–160
   PubMed Web of Science ®Google Scholar
• Stephen P. J., Williamson J. Drug-induced parkinsonism in the elderly. Lancet 1984; 2: 1082–1083
   PubMed Web of Science ®Google Scholar
• Stevens J. R. Neuropathology of schizophrenia. Archives of General Psychiatry 1982; 39: 1131–1139
   PubMed Web of Science ®Google Scholar
• Strauss J. S., Carpenter W. T., Bartko J. J. An approach to the diagnosis and understanding of schizophrenia: Speculations on the process that underlie schizophrenic symptoms and signs. Schizophrenia Bulletin 1974; 1: 61–69
   Google Scholar
• Studler J. M., Javoy-Agid F., Cesselin F., Legrand J. C., Agid Y. CCK-8 immunoreactivity distribution in human brain: selective decrease in the substantia nigra from parkinsonian patients. Brain Research 1982; 243: 176–179
   PubMed Web of Science ®Google Scholar
• Synek V., Reuben J. R. The ventricular brain ratio using planimetric measurements of EMI scans. British Journal of Radiology 1976; 49: 233–237
   PubMed Web of Science ®Google Scholar
• Tandon R., Greden J. F. Trihexyphenidyl treatment of negative schizophrenic symptoms. Acta Psychiatrica Scandinavica 1987; 76: 732
   PubMedGoogle Scholar
• Tandon R., Greden J. F. & K. R. Treatment of negative schizophrenic symptoms with trihexyphenidyl. Journal of Clinical Psychopharmacology 1988; 8: 212–215
   PubMed Web of Science ®Google Scholar
• Tandon R., Greden J. F. Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. Archives of General Psychiatry 1989; 46: 745–753
   PubMed Web of Science ®Google Scholar
• Tandon R., Goodson J., Silk K. R., Kronfol Z., Hariharan M., Greden J. F. Positive and negative symptoms in schizophrenia and the dexamethasone suppression test. Biological Psychiatry 1989; 25: 788–791
   PubMed Web of Science ®Google Scholar
• Taylor A. E., Saint-Cyr J. A., Lang A. E. Frontal dysfunction in Parkinson's disease: The cortical focus of neostriatal outflow. Brain 1986; 109: 845–883
   PubMed Web of Science ®Google Scholar
• Tetrud J. W., Langston J. W. The effects of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989; 245: 519–522
   PubMed Web of Science ®Google Scholar
• Teuber H. L. The riddle of frontal lobe function in man. The frontal granular cortex and behavior, J. M. Warren, K. Akert. McGraw-Hill, New York 1964; 410–444
   Google Scholar
• Todd N. Scottish first episode schizophrenia study: Two-year follow-up. Psychiatry Today: Accomplishments and Promises, C. N. Stefanis, C. R. Soldatos, A. D. Rabavilas. Excerpta Medica, Amsterdam 1989; 287
   Google Scholar
• Tonnard-Neuman E. Phenothiazines and diabetes in hospitalized women. American Journal of Psychiatry 1968; 124: 978–982
   PubMed Web of Science ®Google Scholar
• Tweedy J., Reding M., Garcia C., Schulman P., Deutsch G., Antin S. Significance of cortical disinhibition signs. Neurology 1982; 32: 169–173
   PubMed Web of Science ®Google Scholar
• Tyrrell D. A. J., Parry R. P., Crow T. J., Johnstone E., Ferrier I. M. Possible virus in schizophrenia and some neurological disorders. Lancet 1979; 2: 839–841
   Google Scholar
• U'Prichard D. C., Bechtel W. D., Rouot B. M., Synder S. H. Multiple apparent alpha-noradrenergic receptor binding sites in rat brain. Effect of 6-hydroxydopamine. Molecular Pharmacology 1971; 16: 47–60
   Google Scholar
• Ungerstedt U. Is interruption of the nigrostriatal dopamine system producing the “lateral hypothalamic syndrome”?. Acta Physiologica Scandinavica 1970; 80: 35A–36A
   PubMedGoogle Scholar
• Ungerstedt U. Adipsia and aphagia after 6-hydroxydopamine induced degeneration of nigrostriatal dopamine system. Acta Physiologica Scandinavica 1971; 367(suppl)95–122
   Google Scholar
• Van Dongen P. A. M. The human locus coeruleus in neurology and psychiatry. Progress in Neurobiology 1981; 17: 97–139
   PubMed Web of Science ®Google Scholar
• Van Kammen D. P., Mann L. S., Sternberg D. E., Ninan P. T., Marder S. r., van Kammen W. B., Rieder R. O., Linnoila M. Dopamine beta-hydroxylase activity and homovanillic acid in spinal fluid of schizophrenics with brain atrophy. Science 1983; 220: 974–977
   PubMed Web of Science ®Google Scholar
• Van Kammen D. P., van Kammen W. B., Mann L. S., Seppala T., Linnoila M. Dopamine metabolism in the cerebrospinal fluid of drug-free schizophrenic patients with and without cortical atrophy. Archives of General Psychiatry 1986; 43: 978–983
   PubMed Web of Science ®Google Scholar
• Van Praag H. M., Korf J. Retarded depression and the dopamine metabolism. Psychopharmacologica 1971; 19: 199–203
   PubMedGoogle Scholar
• Van Putten T., May P. R. A. “Akinetic depression” in schizophrenia. Archives of General Psychiatry 1978; 35: 1101–1107
   PubMed Web of Science ®Google Scholar
• Van Putten T., May P. R. A., Willkins J. N. Importance of akinesia: Plasma chlorpromazine and prolactin levels. American Journal of Psychiatry 1980; 137: 1446–1448
   PubMed Web of Science ®Google Scholar
• Venables P. H. The psychophysiological aspects of schizophrenia. British Journal of Medical Psychology 1966; 39: 289–297
   Web of Science ®Google Scholar
• Von Buttlar-Brentano K. Pathohistologische Feststellungen am basalkern Schizophrener. Journal of Nervous and Mental Disease 1952; 116: 646–653
   PubMed Web of Science ®Google Scholar
• Waddington J. L., Youssef H. A. An unusual cluster of tardive dyskinesia in schizophrenia: Association with cognitive dysfunction and negative symptoms. American Journal of Psychiatry 1986; 143: 1162–1165
   PubMed Web of Science ®Google Scholar
• Waddington J. L., Youssef H. A., Dolphin C., Kinsella A. Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality. Archives of General Psychiatry 1987; 44: 907–912
   PubMed Web of Science ®Google Scholar
• Waldhauser F., Weiszenbacher G., Frisch H., Zeitelhuber U., Waldhauser M., Wurtman R. J. Fall in nocturnal serum melatonin during prepuberty and pubescence. Lancet 1984; 2: 362–365
   Google Scholar
• Waziri R. Lateralization of neuroleptic-induced dyskinesia indicates pharmacologic asymmetry in the brain. Psychopharmacology 1980; 68: 51–53
   PubMed Web of Science ®Google Scholar
• Weinberger D. R., Torrey E. F., Neophytides A. N. Lateral cerebral ventricular enlargement in chronic schizophrenia. Archives of General Psychiatry 1979; 36: 735–739
   PubMed Web of Science ®Google Scholar
• Weinberger D. R., Wyatt R. J. Structural brain abnormalities in chronic schizophrenia: Computed tomography findings. Perspectives in Schizophrenia Research, C. Baxter, T. Melnuchek. Raven Press, New York 1980
   Google Scholar
• Weinberger D. R., Cannon-Spoor E., Potkin S. G., Wyatt R. J. Poor premorbid adjustment and CT scan abnormalities in chronic schizophrenia. American Journal of Psychiatry 1980; 137: 1410–1413
   PubMed Web of Science ®Google Scholar
• Weinberger D. R. Computed tomographic (CT) findings in schizophrenia: Speculations on the meaning of it all. Journal of Psychiatric Research 1984; 18: 477–490
   PubMed Web of Science ®Google Scholar
• Weinberger D. R. Implications of normal brain development for the pathogenesis of schizophrenia. Archives of General Psychiatry 1987; 44: 660–669
   PubMed Web of Science ®Google Scholar
• Weigant V. M., Verhoef C. J., Burbach P. H., de Wied D. Increased concentration of alpha and sigma-endorphin in post mortem hypothalamic tissue of schizophrenic patients. Life Sciences 1988; 42: 1733–1742
   PubMed Web of Science ®Google Scholar
• Willkinson D. G. Psychiatric aspects of diabetes mellitus. British Journal of Psychiatry 1981; 138: 1–9
   PubMed Web of Science ®Google Scholar
• Wise C. D., Stein L. Dopamine beta-hydroxylase deficit in the brain of schizophrenic patients. Science 1973; 181: 344–347
   PubMed Web of Science ®Google Scholar
• Wise R. A. Neuroleptics and operant behavior: The anhedonia hypothesis. Behavioral and Brain Sciences 1982; 5: 39–87
   Web of Science ®Google Scholar
• Woodard J. C. Concentric hyaline inclusion body formation in mental disease: Analysis of 27 cases. Journal of Neuropathology and Experimental Neurology 1962; 21: 442–449
   PubMed Web of Science ®Google Scholar
• Zigmond M. J., Acheson A. L., Stachowiak M. K., Strickerm E. M. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Archives of Neurology 1984; 41: 856–861
   PubMedGoogle Scholar